Biotech Co.*
(Country; Symbol)

Pharma Co.
(Country)

Product

Terms/Details (Date)


Cobra Biomanu- facturing* (UK)

Mayne Pharma
(Australia)

Agreement to supply clinical trial and commercial supplies of ovine adenovirus

Mayne is combining a cell-killing technology with the ovine adenovirus technology, which is licensed from a research organization; Cobra will supply ovine adenovirus for the toxicology studies and Phase I/II trials (12/11)

 

GTC
Biotherapeutics
 
Inc.
(GTCB)

Merrimack Pharmaceuticals Inc.

ABI.001

Agreement for GTC to begin production of Merrimack's ABI.001, a recombinant human alpha-fetoprotein to be used in clinical studies; GTC will be compensated in 2003 upon the delivery of clarified bulk product to Merrimack (10/24)

 

Helix BioPharma
Corp.
(Canada)

WellSpring Pharmaceutical Canada Corp. (Canada)

Interferon-alpha 
cream

Agreement for the manufacture of product for clinical studies planned for 2003; WellSpring will manufacture the cream for infection and disease caused by the human papillomavirus (12/17)

 

Hemispherx Biopharma Inc. (AMEX:HEB)

Sigma-Aldrich Fine Chemicals (division of Sigma-Aldrich Corp.)

Ampligen

Sigma-Aldrich Fine Chemicals will manufacture the active ingredient for Hemispherx's lead RNA-based platform drug, Ampligen (11/18)

 

InSite Vision Inc.
(AMEX:ISV)

Societa Industria Farmaceutica 
Italiana SpA (Italy)

OcuGene genetic
glaucoma test

Eight-year agreement in which SIFI gains rights to manufacture, distribute and promote the OcuGene genetic glaucoma test in Italy (12/17)

 

KS Biomedix plc
(UK; LSE:KSB)

Ranbaxy
Laboratories 
Ltd. (India)

TransMID

Marketing agreement in which Ranbaxy will have exclusive marketing rights in India in return for unspecified milestone payments; Ranbaxy also has an option to extend coverage to other Southern Asia markets (10/30**)

 

Lorus Therapeutics Inc. (Canada; OTC BB:LORFF; TSE:LOR)

Mayne Pharma 
(unit of F.H. 
Faulding & Co. 
Ltd.; Australia)

Virulizin

Mayne Pharma will acquire distribution rights for Virulizin in Argentina for the treatment of malignant melanoma (11/14)

 

Microbix
Biosystems Inc.
(Canada; TSE:MBX)

Merck & Co. 
Inc.

Helper-Dependent Adenovirus Vector technology

Agreement for Microbix to distribute the technology for Merck; financial terms were not disclosed (11/15)

 

The Medicines  
Co.
(MDCO)

Oryx Pharma-
ceuticals Inc.

Angiomax

Marketing and promotion agreement under which Oryx will market Angiomax in Canada (10/31)

 

Unigene
Laboratories
 
Inc.
(UGNE)

Upsher-Smith Laboratories Inc.

A nasal version 
of calcitonin

The marketing agreement includes an up- front payment to Unigene of $3M; Unigene will manufacture the product for packaging and distribution nationwide by Upsher-Smith (12/2)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange